Reslizumab (Sch 55700) 是靶向人白介素 5 (IL-5) 的人源化单克隆抗体，用于研究嗜酸性粒细胞性哮喘。Reslizumab 可有效阻断IL-5的功能。Reslizumab 对人IL-5具有高结合亲和力，在 Biacore 表面等离振子共振和动力学排斥分析中，KD值分别为 109 pM 和 4.3 pM。
| 生物活性 | Reslizumab (Sch 55700) is humanized monoclonal antibodies that targetinterleukin-5 (IL-5)for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function ofIL-5. Reslizumab has high binding affinity for humanIL-5, withKDvalues of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2]. |
| IC50& Target[1][2] | |
体外研究
(In Vitro) | Reslizumab (Sch 55700) (0-10 nM, 48 h) inhibits IL-5-dependent cell proliferation, with an IC50value of approximately 91.1pM[1].
Cell Proliferation Assay[1] | Cell Line: | Human erythroleukemic TF-1 cell line | | Concentration: | 0-10 nM | | Incubation Time: | 48 h | | Result: | Showed antiproliferative activity with an IC50of 91.1 pM. |
|
体内研究
(In Vivo) | Reslizumab (Sch 55700) (0-10 mg/kg; i.p. or i.m.) inhibits pulmonary eosinophilia in a dose-dependent manner in allergic mice[3].
Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs[3].
Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs[3].
Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys[3].
| Animal Model: | Male B6D2F1/J mice weighing 20–25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 μg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)[3] | | Dosage: | 0–10 mg/kg | | Administration: | Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.) | | Result: | Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463). |
|
| Clinical Trial | |
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com